Lipocine Inc. Files 8-K
Ticker: LPCN · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Lipocine filed an 8-K, standard procedure, no new info.
AI Summary
Lipocine Inc. filed an 8-K on August 27, 2024, reporting other events and financial statements. The filing does not contain specific details on new events, dollar amounts, or dates beyond the filing date itself.
Why It Matters
This 8-K filing indicates Lipocine Inc. has submitted required documentation to the SEC, but it does not disclose new material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission and does not contain any new material information that would impact risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- August 27, 2024 (date) — Date of Report
- 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
- Salt Lake City, Utah 84108 (address) — Principal executive offices
- 001-36357 (other) — Commission File Number
FAQ
What is the purpose of this 8-K filing for Lipocine Inc.?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of August 27, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 27, 2024.
What is Lipocine Inc.'s principal executive office address?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
Does this filing disclose any new material events or financial information?
Based on the provided text, this filing appears to be a routine submission and does not detail specific new events or financial figures beyond the filing date.
What is Lipocine Inc.'s Commission File Number?
Lipocine Inc.'s Commission File Number is 001-36357.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 10.3 · Accepted 2024-08-27 11:23:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 13KB
- form8-k_002.jpg (GRAPHIC) — 551KB
- 0001493152-24-033967.txt ( ) — 1365KB
- lpcn-20240827.xsd (EX-101.SCH) — 3KB
- lpcn-20240827_lab.xml (EX-101.LAB) — 33KB
- lpcn-20240827_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: August 27, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer